# Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump

> **NCT01430000** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Medgenics Medical Israel Ltd.**

## Conditions studied

- Hepatitis C

## Interventions

- **BIOLOGICAL:** Subcutan implantation of autologus skin graft after ex-vivo treatment

## Key facts

- **NCT ID:** NCT01430000
- **Lead sponsor:** Medgenics Medical Israel Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430000, "Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01430000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*